Babák Myeloma Group
Head: Sabina Ševčíková
Brno node
HOME INSTITUTION
Faculty of Medicine MU
RESEARCH PROGRAMME(S)
RP 3 - Biomarkers of cancers and cancer diagnostics
RP 4 - Early detection and prevention of tumours
Never give up, never surrender!
- Mission: Clarify pathogenesis of monoclonal gammopathies.
- Vision: Identify easily accessible markers for faster and easier diagnostics of monoclonal gammopathies.
Babak myeloma group analyses so-called liquid biopsies that would simplify diagnostics of individual monoclonal gammopathies, especially multiple myeloma. Multiple myeloma (MM) is the second most common hematological malignancy of the elderly, characterized by malignant transformation of plasma cells. In some cases, the cells migrate out of the bone marrow and infiltrate soft tissues – creating so-called extramedullary disease with a worse prognosis for the patients. The diagnosis of the extramedullary disease is quite difficult. The mechanism of loss of dependence on the bone marrow microenvironment has not been identified. In peripheral blood, we are looking for easily measurable and accessible markers that would help with the diagnosis of individual forms of monoclonal gammopathies, especially extramedullary disease.
SELECTED PUBLICATIONS
- Deulofeu M, Kolářová L, Salvadó V, María Peña-Méndez E, Almáši M, Štork M, Pour L, Boadas-Vaello P, Ševčíková S, Havel J, Vaňhara P. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Sci Rep. 2019 May 28;9(1):7975. DOI: 10.1038/s41598-019-44215-1
- Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022 Oct 31:JCO2201226. DOI: 10.1200/JCO.22.01226
- Vlachová M, Gregorová J, Vychytilová-Faltejsková P, Gabło NA, Radová L, Pospíšilová L, Almáši M, Štork M, Knechtová Z, Minařík J, Popková T, Jelínek T, Hájek R, Pour L, Říhová L, Ševčíková S. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. Int J Mol Sci. 2022 Nov 25;23(23):14765. DOI: 10.3390/ijms232314765
- Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014 Mar;99(3):511-8. DOI: 10.3324/haematol.2013.093500
- Sevcikova S., Minarik J., Stork M., Jelinek T., Pour L., Hajek R. Extramedullary disease in multiple myeloma – controversies and future directions Review Blood Rev. 2019 Jul:36:32-39. DOI: 10.1016/j.blre.2019.04.002
SPECIALIZED EXPERTISE AND TECHNOLOGY
Cell cultures
RNA NGS
qPCR
MALDI-TOF MS
COLLABORATION WITH LARGE RESEARCH INFRASTRUCTURES AND RESEARCH CENTRES
Central European Institute of Technology at Masaryk University CEITEC MU